Assessment of Adherence to Gluten Free Diet in Children and Adolescents by Detection of Gluten in Faecal Samples.

Sponsor
Rabin Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT03663309
Collaborator
(none)
194
1
35.5
5.5

Study Details

Study Description

Brief Summary

To assess the adherence to gluten free diet by measuring faecal and urinary gluten immunogenic peptides (GIP). This will provide an objective measure for adherence.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: detecting Gluten peptides in faecal and urine samples

Detailed Description

The adherence to the GFD can be assessed through a dietary interview performed by a registered dietitian or patient self-reports, mucosal healing, assessed by a small bowel biopsy or CD serological screening tests showing decreasing levels of antibodies. However, none of these methods offer an accurate measure of dietary compliance. A novel method to monitor the adherence to the GFD by detection of immune-dominant gluten peptides in human faeces or urine using the anti-α -gliadin G12 antibody was described recently in the literature. Gluten peptides, in particular peptides equivalent to the immunogenic - α -gliadin-33-mer peptide, are resistant to gastrointestinal digestion and that ensures a significant amount of the ingested gluten is excreted in faeces. Consequently, recovery of detectable amounts of the immunogenic fraction in faeces or urine indicates that gluten has passed through the digestive tract, and in the case of urine was absorbed, and, therefore, that gluten has been consumed .

Study Design

Study Type:
Observational
Actual Enrollment :
194 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Assessment of Adherence to Gluten Free Diet in Children and Adolescents by Detection of Gluten Immunogenic Peptides in Faecal Samples and Nutritional Assessment. Retrospective Study
Actual Study Start Date :
Jun 19, 2018
Actual Primary Completion Date :
Jun 3, 2021
Actual Study Completion Date :
Jun 3, 2021

Arms and Interventions

Arm Intervention/Treatment
study group

Children and adolescents aged 2-17 years, reported to be on gluten free diet for at least a year, diagnosed with celiac disease Children and adolescents aged 2-17 years that are reported to be noncompliant with gluten free diet, diagnosed with celiac disease for at least 1 year.

Diagnostic Test: detecting Gluten peptides in faecal and urine samples
At each visit patient will: Bring 4-day food diary (attached) Fill symptoms and complaints questionnaire (attached) Provide 24 h diet recall in case a food diary absents Fill Biagi score questionnaire (attached) Perform blood test of TTG Provide stool and urine samples

control group

Healthy controls aged 2-17 years old matched for age and sex.

Outcome Measures

Primary Outcome Measures

  1. Correlation between fecal gluten peptides and nutritional assessment for gluten free diet, and correlation with celiac serology. [one year]

    Our goal is to examine which method will be the most accurate, nutritional assessment or laboratory tests for the adherence to GFD

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years to 17 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Age 2-17 years.

  • Either diagnosis of celiac disease or, in controls, no systemic disease or inflammation

  • For all groups parents will provide informed consent.

Exclusion Criteria:

° Children with suspected or known inflammatory bowel disease or other gastrointestinal or systemic diseases.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Schneider Children's Medical Center of Israel Petach Tikva Israel 49202

Sponsors and Collaborators

  • Rabin Medical Center

Investigators

  • Study Chair: Liron Mondshine, B.Sc, Rabin Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
raanan shamir, Professor, Rabin Medical Center
ClinicalTrials.gov Identifier:
NCT03663309
Other Study ID Numbers:
  • 0367-17RMC
First Posted:
Sep 10, 2018
Last Update Posted:
Oct 1, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 1, 2021